Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association of MDR1 Gene Polymorphisms with Susceptibility to Hepatocellular Carcinoma in the Chinese Population

  • Ren, Yong-Qiang (Institute of Liver Disease of People's Liberation Army, Beijing Military General Hospital) ;
  • Han, Ju-Qiang (Institute of Liver Disease of People's Liberation Army, Beijing Military General Hospital) ;
  • Cao, Jian-Biao (Institute of Liver Disease of People's Liberation Army, Beijing Military General Hospital) ;
  • Li, Shao-Xiang (Institute of Liver Disease of People's Liberation Army, Beijing Military General Hospital) ;
  • Fan, Gong-Ren (Institute of Liver Disease of People's Liberation Army, Beijing Military General Hospital)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The objective of this study was to evaluate the association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma (HCC). Methods: A total of 689 HCC patients and 680 cancer-free subjects were enrolled. Human MDR1 gene polymorphisms were investigated by created restriction site-polymerase chain reaction (CRS-PCR) and DNA sequencing methods. Multiple logistic regression models were applied to estimate the association between MDR1 gene polymorphisms and susceptibility to HCC. Results: We detected a novel c.4125A>C polymorphism and our findings suggested that this variant was significantly associated with susceptibility to HCC. A significantly increased susceptibility to HCC was noted in the homozygote comparison (CC versus AA: OR=1.621, 95% CI 1.143-2.300, ${\chi}^2$=7.4095, P=0.0065), recessive model (CC versus AC+AA: OR=1.625, 95% CI 1.167-2.264, ${\chi}^2$=8.3544, P=0.0039) and allele contrast (C versus A: OR=1.185, 95% CI 1.011-1.389, ${\chi}^2$=4.4046, P=0.0358). However, no significant increase was observed in the heterozygote comparison (AC versus AA: OR=0.995, 95% CI 0.794-1.248, ${\chi}^2$=0.0017, P=0.9672) and dominant model (CC+AC versus AA: OR=1.106, 95% CI 0.894-1.369, ${\chi}^2$=0.8560, P=0.3549). Conclusions: These findings suggest that the c.4125A>C polymorphism of the MDR1 gene might contribute to susceptibility to HCC in the Chinese population. Further work will be necessary to clarify the relationship between the c.4125A>C polymorphism and susceptibility to HCC on larger populations of diverse ethnicity.

Keywords

References

  1. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al (2003). P-glycoprotein: from genomics to mechanism. Oncogene, 22, 7468-85. https://doi.org/10.1038/sj.onc.1206948
  2. Bosch FX, Ribes J, Diaz M, et al (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, S5-16. https://doi.org/10.1016/S0016-5085(04)01170-9
  3. But DY, Lai CL, Yuen MF (2008). Natural history of hepatitisrelated hepatocellular carcinoma. World J Gastroenterol, 14, 1652-6. https://doi.org/10.3748/wjg.14.1652
  4. Cavaco I, Gil JP, Gil-Berglund E, et al (2003). CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med, 41, 1345-50.
  5. Chen JG, Zhang SW, Chen WQ (2010). Analysis of liver cancer mortality in the national retrospective sampling survey of death causes in China, 2004 -2005. Zhonghua Yu Fang Yi Xue Za Zhi, 44, 383-9 (in Chinese).
  6. Chen XJ, Wang XG, Shen YJ, et al (2011). Correlation of MDR1 single nucleotide polymorphism with prognosis of hepatocellular carcinoma. J Chin Oncol, 17, 209-211.
  7. Chen YD, Yang F, Feng ST, et al (2009). A case-control study on the association between genetic polymorphisms of MDR1 and hepatic cell cancer susceptibility. Chin Clin Oncol, 14, 1077-81.
  8. Chinn LW, Kroetz DL (2007). ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther, 81, 265-9. https://doi.org/10.1038/sj.clpt.6100052
  9. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87. https://doi.org/10.1038/nrc1934
  10. Gomaa AI, Khan SA, Toledano MB, et al (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8. https://doi.org/10.3748/wjg.14.4300
  11. Haliassos A, Chomel JC, Tesson L, et al (1989). Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Res, 17, 3606. https://doi.org/10.1093/nar/17.9.3606
  12. Hoffmeyer S, Burk O, von Richter O, et al (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A, 97, 3473-8. https://doi.org/10.1073/pnas.97.7.3473
  13. Jamroziak K, Mlynarski W, Balcerczak E, et al (2004). Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol, 72, 314-21. https://doi.org/10.1111/j.1600-0609.2004.00228.x
  14. Kaya P, Gunduz U, Arpaci F, et al (2005). Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients. Am J Hematol, 80, 26-34. https://doi.org/10.1002/ajh.20427
  15. Kurzawski M, Drozdzik M, Suchy J, et al (2005). Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol, 61, 389-94. https://doi.org/10.1007/s00228-005-0926-5
  16. Leonessa F, Clarke R (2003). ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer, 10, 43-73. https://doi.org/10.1677/erc.0.0100043
  17. Llovet JM, Burroughs A, Bruix J (2003). Hepatocellular carcinoma. Lancet, 362, 1907-17. https://doi.org/10.1016/S0140-6736(03)14964-1
  18. Nault JC, Zucman-Rossi J (2011). Genetics of hepatobiliary carcinogenesis. Semin Liver Dis, 31, 173-87. https://doi.org/10.1055/s-0031-1276646
  19. Parikh S, Hyman D (2007). Hepatocellular cancer: a guide for the internist. Am J Med, 120, 194-202. https://doi.org/10.1016/j.amjmed.2006.11.020
  20. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  21. Pechandova K, Buzkova H, Slanar O, et al (2006). Polymorphisms of the MDR1 gene in the Czech population. Folia Biol (Praha), 52, 184-9.
  22. Sohn JW, Lee SY, Lee SJ, et al (2006). MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol, 36, 137-41. https://doi.org/10.1093/jjco/hyi231
  23. Suriawinata A, Xu R (2004). An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis, 24, 77-88.
  24. Taniguchi S, Mochida Y, Uchiumi T, et al (2003). Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol Cancer Ther, 2, 1351-9.
  25. Thorgeirsson SS, Grisham JW (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 31, 339-46. https://doi.org/10.1038/ng0802-339
  26. Vander Borght S, Komuta M, Libbrecht L, et al (2008). Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int, 28, 1370-80. https://doi.org/10.1111/j.1478-3231.2008.01889.x
  27. Wu L, Xu X, Shen J, et al (2007). MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol, 96, 62-8. https://doi.org/10.1002/jso.20774
  28. Yu X, Xie H, Wei B, et al (2011). Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS One, 6, e25933. https://doi.org/10.1371/journal.pone.0025933
  29. Yuan ZR, Chu GY, Dan Y, et al (2012). BRCA1: a new candidate gene for bovine mastitis and its association analysis between single nucleotide polymorphisms and milk somatic cell score. Mol Biol Rep, 39, 6625-6631. https://doi.org/10.1007/s11033-012-1467-5
  30. Yuan Z, Li J, Li J, et al (2012). Effects of DGAT1 gene on meat and carcass fatness quality in Chinese commercial cattle. Mol Biol Rep, DOI 10.1007/s11033-11012-12251-11032.
  31. Yuan Z, Li J, Li J, Gao X, Xu S (2013). SNPs identification and its correlation analysis with milk somatic cell score in bovine MBL1 gene. Mol Biol Rep, 40, 7-12. https://doi.org/10.1007/s11033-012-1934-z
  32. Yuan ZR, Li J, Zhang LP, et al (2012). Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle. Gene, 505, 190-4. https://doi.org/10.1016/j.gene.2012.05.010
  33. Zeng X, Liu S, Yu H, et al (2012). DNA repair capacity, DNAstrand break repair gene polymorphisms, and the incidence of hepatocellular carcinoma in southwestern Guangxi of China. DNA Cell Biol, 31, 1384-91. https://doi.org/10.1089/dna.2012.1646

Cited by

  1. Association between single genetic polymorphisms of MDR1 gene and gastric cancer susceptibility in Chinese vol.30, pp.3, 2013, https://doi.org/10.1007/s12032-013-0643-3
  2. Association between ABCB1 Immunohistochemical Expression and Overall Survival in Gastric Cancer Patients vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6935
  3. EGF Reverses Multi-drug Resistance via the p-ERK Pathway in HepG2/ADM and SMMC7721/ADM Hepatocellular Carcinoma Models vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2619
  4. MDR1 C3435T and C1236T Polymorphisms: Association with High-risk Childhood Acute Lymphoblastic Leukemia vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2839
  5. Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma vol.36, pp.9, 2015, https://doi.org/10.1007/s13277-015-3407-1
  6. Effect of shikonin on multidrug resistance in HepG2: The role of SIRT1 vol.53, pp.7, 2015, https://doi.org/10.3109/13880209.2014.952836
  7. Genetic Variation in the ABCB1 Gene May Lead to mRNA Level Chabge: Application to Gastric Cancer Cases vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8467